Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
The role of VHL in clear-cell renal cell carcinoma and its relation to targeted therapy Clark PEKidney Int 2009[Nov]; 76 (9): 939-45The basic biology underlying the development of clear-cell renal cell carcinoma (ccRCC) is critically dependent on the von Hippel-Lindau gene (VHL), whose protein product is important in the cell's normal response to hypoxia. Aberrations in VHL's function, either through mutation or promoter hypermethylation, lead to accumulation of the transcriptional regulatory molecule, hypoxia-inducible factor alpha (HIFalpha). HIFalpha can then dimerize with HIFbeta and translocate to the nucleus, where it will transcriptionally upregulate a series of hypoxia-responsive genes, including vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and others. Binding of these ligands to their cognate receptors activates a series of kinase- dependent signaling pathways, including the RAF-MEK-ERK and phosphatidylinositol-3 kinase-AKT-mTOR pathways. Targeted agents developed and now approved for use in advanced ccRCC include humanized monoclonal antibodies against VEGF, small-molecule tyrosine kinase inhibitors, and inhibitors of mTOR. Understanding the biology of ccRCC is critical in understanding the current therapy for the disease and in developing novel therapeutics in the future. This review will provide an overview of the genetics of ccRCC, with an emphasis on how this has informed the development of the targeted therapeutics for this disease.|*Gene Expression Regulation, Neoplastic[MESH]|Animals[MESH]|Antibodies, Monoclonal/therapeutic use[MESH]|Antineoplastic Agents/adverse effects/chemistry/*therapeutic use[MESH]|Aryl Hydrocarbon Receptor Nuclear Translocator/genetics[MESH]|Carcinoma, Renal Cell/*drug therapy/genetics/metabolism[MESH]|Drug Design[MESH]|Humans[MESH]|Hypoxia-Inducible Factor 1, alpha Subunit/genetics[MESH]|Kidney Neoplasms/genetics/metabolism/*therapy[MESH]|Protein Kinase Inhibitors/therapeutic use[MESH]|Protein Kinases/drug effects/genetics[MESH]|Receptors, Vascular Endothelial Growth Factor/antagonists & inhibitors/genetics[MESH]|Signal Transduction/*drug effects/genetics[MESH]|TOR Serine-Threonine Kinases[MESH]|Translational Research, Biomedical[MESH]|Treatment Outcome[MESH]|Vascular Endothelial Growth Factor A/antagonists & inhibitors/genetics[MESH]|Von Hippel-Lindau Tumor Suppressor Protein/*genetics/metabolism[MESH] |
